Company: FTII
Filing Date: 2025-02-14
Form Type: S-4
Source: 0001493152-25-006997
Chunk: 46

Company: FutureTech II Acquisition Corp.
Filing Date: 2025-02-14
Form: S-4
Chunk 46
---
 for soft tissue reconstruction, Aureva Pulse for ischemic stroke, Reflow RVO for retinal veinocclusion and a biosynthetic cornea;

| ● | LBI-101                                                                                           
 is designed as an off-the-shelf substitute for autologous fat grafting and a potential tissue     
 replacement solution for treatment of soft tissue defects, reconstructive surgery and aesthetics; |

| 6 |

| ● | LBI-201                                                                                     
 is a therapeutic ultrasound device that is designed to be used in combination with tissue   
 plasminogen activator during the acute phase of ischemic stroke to break-up blood clots and 
 restore blood flows to the ischemic regions of the brain; and                               |

| ● | LBI-001                                                                                     
 is designed to treat the venous blood clot in the retinal vein by combining the intravenous 
 administration of microspheres with non-invasive therapeutic ultrasound delivered across    
 the closed inferior eyelid,                                                                 |

Experienced and Proven Management Team. The combined company’s management team will combine expertise and experience in the discovery, development, manufacturing and commercialization of biotechnology products. Over a twelve-month period prior to the entry of the Merger Agreement, the FutureTech management team has had the opportunity to engage and evaluate the Longevity team. In addition, the entire senior management team of Longevity is expected to continue with the company following the Business Combination to execute the business and strategic growth plan; the combined company will be led by Bradford A. Zakes as its Chief Executive Officer, who has spent over thirty years in various segments of the pharmaceutical, biotechnology and med-tech industries. Dr. Francesco Curra will serve as the Chief Technology Officer and is a recognized medical ultrasound professional with approximately twenty years of academic and private sector R&D experience in the fields of ultrasound imaging, high intensity focused ultrasound, nonlinear acoustics and tissue bioeffects. Lock-Up. The Longevity management and certain Longevity stockholders have agreed to a six-month lock-up period with respect to their shares of combined company Common Stock, subject to customary exceptions which will provide important stability to combined company for a period of time following the Business Combination; and holders of the founder shares have agreed to founder shares lock-up period, which is the period ending on the earlier of (A) the one-year anniversary of the date of the consummation of the Business Combination or (B) subsequent to the Business Combination, (x) if the reported last sale price of the Common Stock equals or exceeds $12.00 per share